UK all-comers Sirolimus-Eluting Balloon Registry: UK-SEB Registry

  • Research type

    Research Study

  • Full title

    UK prospective registry on sirolimus drug-coated balloon (UK all-comers Sirolimus-Eluting Balloon Registry: UK-SEB Registry)

  • IRAS ID

    251988

  • Contact name

    Sandeep Basavarajaiah

  • Contact email

    sandeep270478@gmail.com

  • Sponsor organisation

    Acrostak Uk Ltd.

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    UK-SEB Registry is initiated with a purpose of evaluating the performance of a Sirolimus Coated Balloon (SCB) for the treatment of coronary stenosis, including both de novo (narrowing within the native vessel) and restenotic lesions (narrowing within the previously placed stent). The study is a prospective, multi centre, spontaneous clinical registry that will enrol real world, all comer patients at various interventional cardiology sites in England. The study targets the enrolment of 700 patients. Patients will be followed up after hospital discharge for up to 24 months: clinic visits or phone calls will be scheduled at 1, 6, 12 and 24 months. The investigational device in the study is the world’s first Sirolimus coated balloon (Magictouch) which is a CE marked. The Magictouch SCB that will be used in this study is a semi-compliant polyamide balloon-catheter with low tip profile (0.016”), coated with Sirolimus drug (drug dose of 180μg on 3.0 x 15 mm balloon, drug to excipient ratio of 1:1). Before participating, all subjects will be informed about the study and will be asked to provide a written informed consent. They will only be enrolled if they consent for the study. After enrolment, the procedure will consist of a planned coronary angioplasty as per the international guidelines or local hospital protocol. Post-procedure, they will undergo the usual formalities as per the hospital and/or local guidelines. All patients’ data will be reported on the CRF (case report form), which is an online electronic portal to enter patient’s data for the research purpose. This can be accessed only by the members of the research team and patient’s identification will be anonymised.

  • REC name

    West Midlands - Solihull Research Ethics Committee

  • REC reference

    19/WM/0004

  • Date of REC Opinion

    20 Feb 2019

  • REC opinion

    Further Information Favourable Opinion